Jump to a section
- What is Ipamorelin?
- Why researchers study it
- Benefits discussed in literature
- Uses discussed in research
- Mechanisms discussed in published studies
- Reported study designs and protocol examples
- Protocol table from cited sources
- Limitations and research gaps
- Documentation checklist
- Related research supplies
- More Ipamorelin research
- Sources and references
Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.
This article summarizes published research and reported study designs. It is not medical advice, dosing guidance, or a personal-use recommendation.
Source-limited research note: The reviewed sources were incomplete, ambiguous, or insufficient for a normal article. This page labels missing details rather than guessing.
Ipamorelin is described in the literature as a synthetic pentapeptide growth hormone (GH) secretagogue that selectively stimulates GH release via a GHRP-like receptor and has been evaluated primarily in preclinical models and narrative reviews; clinical trial evidence is limited or lacking in the reviewed sources. [S2,S3,S4]
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide GH secretagogue (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that was developed as a potent stimulator of growth hormone release with selectivity for GH secretion and minimal effects on ACTH and cortisol in the original pharmacology studies. [S2] [S2]
Ipamorelin is routinely categorized alongside other growth hormone secretagogues (GHS) in reviews of peptide therapeutics and is discussed in contexts including endocrinology, gerontology, orthopaedics, and sports medicine. [S1,S3,S4,S7] [S1] [S3] [S4] [S7]
Why researchers study it
Researchers study ipamorelin because GHS compounds modulate the GH/IGF-1 axis, a pathway of interest for tissue repair, body-composition management, and age-related hormonal decline; ipamorelin's apparent GH-selectivity makes it of particular mechanistic and translational interest. [S1,S2,S6,S7] [S1] [S2] [S6] [S7]
Preclinical models also examine potential utility of ipamorelin-like compounds in mitigating weight loss associated with chemotherapy and in other contexts where stimulation of appetite, lean mass, or repair processes may be relevant. [S8,S3] [S8] [S3]
Benefits discussed in literature
Ipamorelin and other GH secretagogues are reported to stimulate GH release and engage downstream IGF-1 signaling relevant to muscle and satellite cell repair in preclinical and mechanistic discussions. [S2,S1,S6,S7] [S2] [S1] [S6] [S7]
Reviews and narrative summaries highlight potential benefits discussed in preclinical work and animal studies, including effects on body composition and muscle function; however, these sources emphasize that human clinical evidence is sparse. [S3,S4,S6] [S3] [S4] [S6]
A preclinical study in ferrets reported that intraperitoneal administration of ipamorelin reduced cisplatin-associated weight loss during the delayed phase by approximately 24% relative to vehicle in that model. [S8] [S8]
Uses discussed in research
In the literature, ipamorelin is discussed as a candidate GH secretagogue for research in endocrinology, body-composition management (including hypogonadism-associated changes), and gerontology, often as an investigational adjunct rather than an approved therapy. [S6,S7,S5] [S6] [S7] [S5]
Orthopaedic and sports-medicine reviews list ipamorelin among peptides considered for regenerative medicine and recovery-enhancing approaches, though these reviews stress the predominance of preclinical data and the absence of robust clinical trials supporting routine clinical use. [S1,S3,S4] [S1] [S3] [S4]
Preclinical experimental use includes testing ipamorelin (and related GHS) to ameliorate chemotherapy-induced anorexia/weight loss and to assess effects on gut motility and feeding behavior in animal models. [S8] [S8]
Mechanisms discussed in published studies
Mechanistic reports indicate ipamorelin acts via a GHRP-like receptor to stimulate GH release from pituitary cells, with potency and efficacy characterized in in vitro and in vivo preclinical pharmacology studies. [S2] [S2]
Reviews place ipamorelin within broader peptide-driven pathways relevant to tissue regeneration, noting growth hormone–IGF-1 signaling and satellite cell repair among downstream processes; other peptide classes act on PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK pathways important for regeneration and metabolic regulation. [S1,S7] [S1] [S7]
In a preclinical ferret model, central nervous system penetration was implicated in anti-emetic effects for a related ghrelin mimetic (anamorelin), and central administration of anamorelin—but not peripheral dosing—reduced acute emesis, suggesting that brain access can determine certain centrally mediated effects in this drug class. [S8] [S8]
Reported study designs and protocol examples
Most empirical ipamorelin data in the reviewed sources are preclinical pharmacology and animal experiments; narrative reviews repeatedly note a shortage of rigorous human clinical trial data and limited reporting of dosing/frequency/duration for clinical use. [S2,S3,S4,S7] [S2] [S3] [S4] [S7]
Representative experimental details present in the reviewed primary research include intraperitoneal administration of ipamorelin (1–3 mg/kg) in ferrets given cisplatin (5 mg/kg, i.p.), administered 30 seconds before cisplatin and then every 24 hours with observation up to 72 hours; additional experiments included intracerebroventricular dosing of anamorelin (10 µg) to probe central mechanisms. [S8] [S8]
Foundational pharmacology reported in the original ipamorelin development study includes in vitro GH release from primary rat pituitary cells (EC50 ≈ 1.3 nmol/L, Emax ≈ 85%) and in vivo ED50 and Emax estimates in pentobarbital-anaesthetized rats and conscious swine; these reports also emphasize ipamorelin's selective GH release relative to other anterior pituitary hormones. [S2] [S2]
Combination and functional outcome experiments are summarized in narrative reviews—for example, a murine model with glucocorticoid-induced muscle loss showed improved maximum tetanic tension with combined CJC-1295 and ipamorelin in preclinical reports cited by reviews—but the original review excerpt does not provide dosing, route, frequency, or duration details. [S3] [S3]
Protocol table from cited sources
The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.
| Source | Study Type | Model / Subject | Amount Reported | Route Reported | Frequency | Duration | Notes |
|---|---|---|---|---|---|---|---|
| [S2] | preclinical pharmacology | in vitro primary rat pituitary cells; pentobarbital-anaesthetized rats; conscious swine | In vitro EC50 ≈ 1.3 ± 0.4 nmol/L (Emax ≈ 85%); rat ED50 ≈ 80 ± 42 nmol/kg (Emax ≈ 1545 ± 250 ng GH/ml); swine ED50 ≈ 2.3 ± 0.03 nmol/kg (Emax ≈ 65 ± 0.2 ng GH/ml) | not reported in the reviewed source | not reported in the reviewed source | not reported in the reviewed source | Ipamorelin stimulated GH release via a GHRP-like receptor and did not significantly increase ACTH or cortisol in the reported assays, distinguishing its specificity relative to other GHRP compounds. [S2] |
| [S8] | preclinical research (animal model) | ferrets (cisplatin-induced emesis/weight-loss model) | Ipamorelin 1–3 mg/kg (i.p.); anamorelin 1–3 mg/kg (i.p.); cisplatin 5 mg/kg (i.p.); anamorelin 10 µg (intracerebroventricular in separate experiment). | Intraperitoneal (i.p.) for systemic dosing; intracerebroventricular for central anamorelin experiment. | Administered 30 seconds before cisplatin and then every 24 hours. | Behavior and intake recorded up to 72 hours; effects on delayed-phase weight loss reported for 48–72 hours. | Systemic ipamorelin and anamorelin reduced cisplatin-associated delayed-phase weight loss by ~24% in ferrets; anamorelin given intracerebroventricularly reduced acute emesis and improved acute-phase food/water intake, suggesting central mechanisms for some effects. EFS-induced ileum contraction inhibition and IC50 values were reported for both compounds. [S8] |
| [S3] | preclinical (murine) reported in narrative review | murine models with glucocorticoid-induced muscle loss | not reported in the reviewed source | not reported in the reviewed source | not reported in the reviewed source | not reported in the reviewed source | Narrative review summarizes that combination CJC-1295 + ipamorelin improved maximum tetanic tension in the cited murine model, but the excerpted review does not provide protocol-level details. [S3] |
Limitations and research gaps
- Most evidence in the reviewed sources is preclinical (in vitro and animal) or narrative review–level; high-quality human clinical trials of ipamorelin for musculoskeletal, metabolic, or gerontological indications are lacking.
- Dosing, routes, frequency, and duration suitable for humans are not reported in the reviewed sources and remain undefined in these excerpts.
- Safety data from rigorous human trials are not provided in the reviewed excerpts; reviews caution about limited human safety and efficacy evidence for many investigational peptides.
- Regulatory and approval status for investigational/unapproved peptide uses is not fully described in the reviewed excerpts and varies by compound and indication.
Documentation checklist
- Confirm whether peer-reviewed human clinical trials exist for the specific ipamorelin indication of interest.
- Verify regulatory status and approved indications from official health authorities before considering clinical use.
- Review primary-source study protocols for exact dosing, route, frequency, and duration before designing translational studies.
- Assess safety data and long-term monitoring plans in the available literature when evaluating investigational peptide use.
Related research supplies
- Lab-grade cryovials and inventory labels for compound storage
- Temperature-monitoring loggers for cold-chain storage
- Sealed secondary containment boxes for chemical/biological inventory
- Laboratory surface disinfectant compatible with bench materials
- Personal protective equipment (gloves, lab coat, eye protection) for handling research compounds
Research organization supplies: Common tools used for research documentation workflows may include lab notebooks, label makers, sample storage boxes, inventory stickers, and temperature log sheets.
Paid-link disclosure: Peptide Bio Index may earn a commission from qualifying purchases. As an Amazon Associate I earn from qualifying purchases.
Compact vial organization
Leng Ke 10-Slot Clear Vial Case
A transparent 10-slot organizer sized for compatible 1–3 mL glass vials. Confirm vial dimensions and documented storage requirements before selection.
Bulk technical cleaning
MG Chemicals 99.9% IPA Wipes
A bulk box of presaturated IPA wipes for compatible technical-cleaning tasks. Confirm material compatibility and ventilation requirements.
Batch and inventory labeling
Phomemo M110 Label and Barcode Printer
A compact thermal label printer for inventory identifiers, storage-box labels, batch references, and document-folder organization.
Product listings, specifications, and availability can change. Review the current Amazon listing and manufacturer instructions before ordering. These links are for research organization and compatible surface/equipment-cleaning workflows, not personal-use guidance.
Research Supply Note: For research-use-only sourcing, review current SourcePoint Research inventory and batch documentation at SourcePointResearch.com. Peptide Bio Index is affiliated with SourcePoint Research.
Sources and references
- [S1] Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026. PMID: 41490200. DOI: 10.5435/JAAOSGlobal-D-25-00236
- [S2] Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M. Ipamorelin, the first selective growth hormone secretagogue.. European journal of endocrinology. 1998. PMID: 9849822. DOI: 10.1530/eje.0.1390552
- [S3] Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.. The American journal of sports medicine. 2026. PMID: 41476424. DOI: 10.1177/03635465251357593
- [S4] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.. Sports medicine (Auckland, N.Z.). 2026. PMID: 41966639. DOI: 10.1007/s40279-026-02437-0
- [S5] Renke G, Chinellato L. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.. International journal of molecular sciences. 2026. PMID: 42123471. DOI: 10.3390/ijms27093890
- [S6] Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.. Translational andrology and urology. 2020. PMID: 32257855. DOI: 10.21037/tau.2019.11.30
- [S7] Mavrych V, Shypilova I, Bolgova O. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.. Frontiers in aging. 2026. PMID: 42021992. DOI: 10.3389/fragi.2026.1790247
- [S8] Lu Z, Ngan MP, Liu JYH, Yang L, Tu L, Chan SW. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.. Physiology & behavior. 2024. PMID: 39043357. DOI: 10.1016/j.physbeh.2024.114644
Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.